Delcath Systems, Inc. (NASDAQ:DCTH), which is a leading interventional oncology company today announced that the American Journal of Clinical Oncology has succeeded in the publication of a comprehensive review which revealed that a large number of authors were at agreement regarding PHP with Melphalan/HDS and its effects. They concluded that PHP with Melphalan/HDS did much towards giving promising results. Expectations are now that there will be the doubling of overall survival and also an elongated hepatic progression-free survival and a progression-free survival. There is great need to come up with more of the less invasive procedures when dealing with the liver. Percutaneous hepatic perfusion (PHP) is making this dream a reality since its procedures are such that they isolate the liver from the body’s circulatory system which makes it possible for the dose of chemotherapy (melphalan hydrochloride) to be infused to the liver in a direct way.

Dr. Jennifer K. Simpson, who is President and the CEO of Delcath said, “The vast majority of patients with metastatic ocular melanoma survive less than a year, due to the difficulty in treating metastases to the liver, which are a hallmark of this cancer. It is therefore especially gratifying to see patients with this rare disease survive almost two years after receiving PHP with Melphalan/HDS,”

PHP with Melphalan/HDS was great innovation by Delcath Systems which aims at introducing a complete liver therapy.

The company’s efforts are not in vain since a lot of patients stand to benefit from its operations and asides from that it may gain more visibility in the American market. Dr. Jennifer K. Simpson in a statement concurred, “We are hopeful that our ongoing Global Phase 3 FOCUS study for patient with ocular melanoma liver metastases will yield similar results, further reinforcing the benefits of our technology, and bringing us one step closer to U.S. market availability.”

Delcath Systems, Inc. concerns itself with the treatment of both the primary metastatic liver cancer, conditions that have proved quite problematic to quite large percentage of people globally. The company is not about stop in its quest to develop much better solutions for patients. One of the benefits that might come with its efforts is a rise in the NASDAQ Stock standings. The future seems bright for patients but we just have to wait and see what ensues with the passage of time.